Bicalutamide Stage 1 - tumors involve the layer beyond the lining of the bladder and beyond but do not involve the muscles of the bladder. OBJECTIVES 2.1 Primary Objective 9 18 03 ; 2.1.1 Determine whether 3D-CRT IMRT to 79.2 Gy in 44 fractions will lead to improved overall survival in patients treated for prostate cancer compared to a group of patients treated with 3D-CRT IMRT to 70.2 Gy in 39 fractions. 2.2 Secondary Objectives 7 10 07 ; 2.2.1 Determine freedom from PSA failure ASTRO consensus definition; See Endpoints, Section 13.0 ; , disease-specific survival, local progression, and distant metastases. 2.2.2 Collect dose volume data to allow tumor control probability and normal tissue complication probability modeling for patients treated with radiation therapy for prostate cancer. 2.2.3 Determine the incidence of grade 2 or greater GU and GI acute and late toxicity in patients treated with each of the regimens described above. 2.2.4 Prospectively collect quality of life data, including sexual function, to compare outcomes between the two treatment groups. Prospectively collect diagnostic biopsy samples to determine the influence of histopathologic or tumor2.2.5 specific cytogenetic or chromosomal markers on cancer control outcomes following radiation. 2.2.6 To collect paraffin-embedded tissue blocks, serum, plasma, and buffy coat cells for future translational research analyses. PATIENT SELECTION 3.1 Conditions for Patient Eligibility 3.1.1 Histologically confirmed prostate adenocarcinoma within 180 days of randomization; 3.1.2 Zubrod Performance Scale 0-1; 3.1.3 Prostatic biopsy tumor grading by the Gleason Score Classification; 3.1.4 One of the following combinations of factors: Clinical stage T1b-T2b, Gleason score 2-6, and prostate-specific antigen 10 but 20; Clinical stage T1b-T2b, Gleason score 7 and prostate-specific antigen 15; 3.1.5 Pretreatment evaluations must be completed as specified in Section 4.1; 9 18 ; Patients must sign a study-specific informed consent form prior to randomization. 3.1.6 3.2 Conditions for Patient Ineligibility 3.2.1 Evidence of distant metastases; 3.2.2 Regional lymph node involvement; 3.2.3 Previous radical surgery prostatectomy ; or cryosurgery for prostate cancer; 3.2.4 Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy; 3.2.5 Previous hormonal therapy, such as LHRH agonists e.g. goserilin, leuprolide ; , anti-androgens e.g. flutamide, bicalutamide ; , estrogens e.g. DES ; , or surgical castration orchiectomy 3.2.6 Use of 5-alpha-reductase finasteride dutasteride [Proscar] ; or the phytoestrogen preparation "PC-SPES" within 3 months prior to registration; 4 18 06 ; 3.2.7 Previous or concurrent cytotoxic chemotherapy for this cancer; 3.2.8 Previous or concurrent invasive cancers, other than localized basal cell or squamous cell skin carcinoma, unless continually disease free for at least 5 years; 3.2.9 Major medical or psychiatric illness that, in the investigator's opinion, would prevent completion of treatment and interfere with follow up. PRETREATMENT EVALUATIONS Protocol treatment must begin within 4 weeks after registration. 9 18 03 ; 4.1 Evaluations Required for Eligibility 9 18 03 ; 4.1.1 Complete history, physical examination, and evaluation of Zubrod Performance Scale; 4.1.2 Histological evaluation of prostate biopsy with assignment of a Gleason score to the biopsy material; 4.1.3 Digital rectal examination of prostate; 4 18 06 ; 4.1.4 Radionuclide bone scan must be done if PSA 10 AND Gleason score 7. 4.2 Other Pretreatment Evaluations 7 10 07 ; 4.2.1 Lymph node assessment is recommended by pre-registration diagnostic pelvic CT scan or MRI and or pelvic lymphadenectomy; 4.2.2 Urethrogram is strongly encouraged at the time of simulation or CT scan for treatment; 4.2.3 PA and lateral chest X-rays are optional; 4.2.4 Quality of life evaluations: International Index of Erectile Function Questionnaire IIEF ; [PQ]; Functional Alterations due to Changes in Elimination FACE ; [FA]; The Spitzer Quality of Life Index SQLI ; [SP]. 8. Tingomaria hydrophila Mello-Leito, 1948 Tingomaria hydrophila Mello-Leito, 1948: 319; Roewer, 1959: 69 Goyazelloides peruvicus Soares & Bauab-Vianna, 1972c: 334, figs 16-17; Soares & Soares, 1979a: 394 figs 9-10 types MNRJ 5277, % holotype 2 & paratype; HSPC 317, 1 & paratype ; . NEW SYNONYMY TYPE LOCALITIES -- Tingomaria hydrophila: PERU. HUNUCO. Tingo Maria: in cave. Goyazelloides peruvicus: PERU. HUNUCO. Tingo Maria, Rio Huallaga, 670 m RECORDS -- PERU. HUNUCO. Cueva de las Lechuzas, near Tingo Maria, 670 m [and not 6700 as stated by Roewer] Huallaga basin Roewer, 1959. I would probably go to oahu for a few days so my husband could see pearl harbor, which i definitely recommend seeing, but then i’ d want to fly to maui or another less-crowded island in hawaii. Off protocol, in patients with high-risk T1c or T2 disease, I use six months of combined hormonal blockade because that is what I used in the study I conducted. In that study, about 27 percent of the patients did not complete the six months of flutamide, mainly because of elevations in their liver function tests LFTs ; . They weren't necessarily having toxicities from the flutamide, but we had a rule: If the LFTs exceeded two times the upper limit of normal, we discontinued the drug for that patient. Despite that, the survival benefit was still seen. It is an open question whether combined hormonal blockade is really necessary; however, without an answer from a randomized trial, I follow the randomized trial results we have. When we designed that trial in 1994, bicalutamide wasn't available, so flutamide was used. Today, bicalutamide is used because it's a once-a-day drug and it doesn't have the same LFT issues. In patients who have T3 or T4 disease by palpation, I use exactly what the RTOG utilized in their randomized study: two months of neoadjuvant combined hormonal blockade, two months of combined hormonal blockade concurrent with radiation therapy and two years of an LHRH agonist alone. Amount of Generation's total mark-to-market asset or liability. Second, this table provides the maturity, by year, of Generation's net assets liabilities, giving an indication of when these markto-market amounts will settle and generate or require cash and acetaminophen. I also was wanting to know what are the best vitamins to take that fights skin aging. UTMB DEPARTMENT OF PHARMACY POLICY AND PROCEDURES Section 07.00 Medication Use Page 10 of 11 Policy 07.52 Ordering Cytotoxic and Effective Date: 04 30 99 Last Review Revision Date: 04 30 01 Hazardous Agents Next Review Date: 10 20 05 Author: Department of Pharmacy Irinotecan Lomustine Mechlorethamine Melphalan Mercaptopurine Methotrexate Mitomycin Mitotane Mitoxantrone Oxaliplatin Paclitaxel Pegaspargase Pentostatin Plicamycin Procarbazine Rituximab require approval ; Streptozocin Teniposide Temozolomide Thioguanine Thiotepa Topotecan Trastuzumab require approval ; Tretinoin Trimetrexate Uracil Mustard Vinblastine Vincristine Vinorelbine Attachment B Exceptions to Cytotoxic and Hazardous Agents Chemotherapy Order form recommended Exceptions: Anastrazole Bjcalutamide Dexrazoxane non-formulary ; Equine anti-thymocyte globulin Examestane Finasteride Fluoxymesterone and methocarbamol. Bicalutamide oral Downloaded from mcb.asm by on July 26, 2008 FIG. 1. Functional characterization and intracellular localization of GFP-AR. A ; Tetracycline-regulated expression of GFP-AR. Total cell extracts were prepared from GFP-AR-expressing 3108 cells in the presence lanes 1 and 3 ; or absence lanes 2 and 4 ; of tetracycline. The extracts were probed for GFP-AR by using anti-AR lanes 1 and 2 ; or anti-GFP lanes 3 and 4 ; antibodies by Western blotting. -Actin was used as a loading control lower panels ; . B and C ; GFP-AR maintained wild-type response to various AR ligands. 3108 cells were transfected with MMTV-LUC B ; or -285PB-LUC C ; constructs and treated with R1881 10 8 M ; , DHT 10 8 M ; , TST 10 8 M ; , CPA 10 6 M ; , RU486 10 6 M ; , bicalutamide 10 6 M ; , OHF 10 6 M ; for 24 h. The cells were harvested, and reporter gene activity was assayed and normalized to total protein amount. The results represent the averages of the results of three replicate experiments, with bars representing standard deviations. The experiments were repeated twice with similar results. D to K ; GFP-AR translocates to the nucleus in response to AR ligands. 3108 cells were treated with ligands as described for panels B and C, and the translocation of GFP-AR was followed by in vivo time-lapse confocal microscopy at 37C. GFP-AR was completely translocated to the nucleus after 30 min in response to R1881 E ; , DHT F ; , TST G ; , and RU486 I ; and after 120 min in response to CPA H ; , bicalutamide Casodex [CAS] ; J ; , and OHF K ; . No translocation was observed in the absence of ligand D ; . Bar in panel K, 4 m. Description: The prostate cancer PCA ; market was estimated to be worth US billion in 2006, with a growth rate of over 5% YoY. It is one of the larger segments of the oncology market, alongside breast, non -small cell lung and colorectal cancers. PCA is the second leading cause of cancer in men in the US and the third most common cancer worldwide. More than two million men in the US suffer with PCA and, according to the American Cancer Society, 234, 460 new cases were diagnosed in the US in 2006, with an estimated 27, 350 deaths. The market is currently driven by the use of hormonal therapies: AstraZeneca's Zoladex goserelin ; and Casodex bicalutamide ; , TAP Pharmaceutical Products' Abbott Takeda ; Lupron leuprolide subcutaneous injection or intramuscular depot ; , sanofi-aventis Astellas Pharma's Eligard leuprolide subcutaneous depot ; and Bayer Schering Pharma's Viadur leuprolide subcutaneous implant ; . In addition, sanofi-aventis' Taxotere docetaxel ; is now licensed and has become the standard treatment for hormone-refractory prostate cancer. In 2006, sales of PCA drugs were dominated by hormonal therapies luteinising hormone-releasing hormone agonists antagonists and anti-androgens ; prescribed mainly for advanced hormonedependent PCA. The arrival of innovative targeted therapies will not make these traditional therapies redundant. Newer therapies will be launched mainly into the hormone-refractory market, an area of current unmet need, whereas hormonal therapies will maintain sales value by continuing their expansion into the treatment of localised disease, while still dominating advanced hormonedependent PCA. Key questions answered include: The patient population suffering from PCA is increasing at 4.8% per year. What clinical and sociological factors are influencing this? What are the strengths and weaknesses of Dendreon's Provenge and Cell Genesys' GVAX and which is likely to dominate? What pipeline products will AstraZeneca introduce to maintain its leading position in the PCA market despite generic competition to Casodex 2008 ; and Zoladex 2011 ; ? CURRENT PRODUCTS EVALUATED AND FORECAST LHRH ANALOGUES Eligard sanofi-aventis Astellas Pharma ; Lupron TAP Pharmaceutical Products ; Zoladex AstraZeneca ; ANTI-ANDROGENS Casodex AstraZeneca ; CHEMOTHERAPY Taxotere sanofi-aventis and tizanidine. [16] at the time of publication february 2008 ; bicalutamide did not haveuk marketing authorisation for this indication. Prostate and Other Genitourinary Tract Cancers DNA optical density OD ; increased significantly by 1% on treatment and decreased by 3% in control subjects estimated mean changes are 2.15 vs. -0.71 respectively, p for interaction time * treatment 0.005 ; , suggesting a reduced transcriptional activity in the nucleus of normal secretory cells on treatment with bicalutamide, consistent with a significant decrease of both PSA and PAP observed on treatment. Conclusions: Nuclear morphometry appears to be feasible on prostate needle biopsies. Treatment with bicalutamide induced significant karyometric changes, supporting further investigation of this procedure as a surrogate biomarker of treatment effect in chemoprevention trials. B38 Randomized, controlled intervention study of soy protein isolate in men at high risk for biochemical recurrence after radical prostatectomy: Design and accrual. M. C. Bosland, 1 A. ZeleniuchJacquotte, 2 J. Melamed, 2 V. Macias, 1 A. Kajdacsy-Balla, 1 J. Schmoll, 2 H. W. Meserve, 2 E. E. Enk1. 1University of Illinois College of Medicine, Chicago, IL, 2New York University School of Medicine, New York, NY. Various lines of evidence suggest that soy intake may prevent prostate cancer and be beneficial for men with prostate cancer and soy constituents inhibit development of prostate cancer in animal models. We designed a double-blind, randomized placebo-controlled clinical trial to determine whether intervention with soy protein reduces biochemical recurrence PSA failure ; in men who are at high risk for such failure in the first two years after radical prostatectomy. To be eligible, subjects must fulfill one or more of the following characteristics: high Gleason sum 8 ; , established extraprostatic extension, seminal vesicle invasion, established positive surgical margins, positive lymph nodes, and or preoperative PSA of 20 ng ml. Using a review of current literature and recent historical data from NYU, it was estimated that the two-year PSA failure rate in subjects fulfilling one or more of these criteria is approx. 30%. Other eligibility criteria are a baseline PSA of less than 0.07 ng ml and confirmation of pathological characteristics by centralized slide review. Exclusionary factors include: regular soy intake at baseline, recent history of soy or milk protein allergy, iron deficiency anemia, diabetes, thyroid disease, or frequent substantive constipation. Biochemical recurrence was defined a priori as reaching a PSA of 0.07 ng ml using an ultra-sensitive assay Tosoh ; , confirmed twice at 1 month intervals. With a sample size of 256 evaluable subjects, this study will have 80% power to detect a 50% reduction in two-year PSA failure rate at a 2-sided significance level of 0.05. To accommodate a known drop-out of 13%, the accrual goal is 284. Thus far, 173 men have been randomized to soy protein isolate or a casein-based placebo Solae ; that are identical in composition, except for protein source, and provide 20 g protein day with the soy preparation containing ~24-26 day genistein and ~40-43 day total isoflavones. Self-reported compliance is excellent, and serum isoflavones including equol ; are being measured by HPLC with electrochemical detection as an independent compliance measure. Of 123 subjects with detectable serum genistein levels from whom equol values were determined thus far, 31% did not have detectable serum equol less than 1 ng ml ; , 41% had equol levels between 1 and 10 ng ml, and 28% had equol level above 10 ng ml range 11-417 ng ml ; . Besides UIC and NYU, 2 other academic medical centers and 2 VA Medical Centers are involved in this study. Thus far, 160 men have completed two years of intervention or developed PSA failure. No treatment-related adverse events were observed, except two cases of transient constipation. Of 33 men thus far identified with biochemical failure PSA 0.07 ; 22 developed further evidence of recurrence while the other man is being followed for this. Continued accrual is ongoing at six US institutions. Supported in part by NIH Grants No. CA27790 and CA116195 by the Fremont Family Foundation. The past donation of the intervention materials by The Solae Company is gratefully acknowledged and metaxalone. Interaction between the AR N- and C-termini in the AR homodimer 15; 19-22 ; . Nonetheless, the AR N-C interaction is not absolutely required for transcriptional activity as ligands that do not support the interaction can still stimulate AR when used at relatively high concentrations, and peptides that block the N-C interaction do not necessarily inhibit AR transcriptional activity 23; 24 ; . These results have suggested that the AR N-C interaction, in conjunction with helix 12, may serve to stabilize agonist ligand binding and receptor conformation at physiological agonist concentrations. The AR plays a central role in normal prostate development and in the development and progression of prostate cancer, with the majority of prostate cancer patients responding to therapies that decrease androgen levels medical or surgical castration ; or directly block AR functions AR antagonists ; 25 ; . However, the molecular mechanisms and transcriptional targets mediating AR effects on normal versus neoplastic prostate growth remain unclear. Bicalutamide, flutamide, and cyproterone acetate CPA ; are the AR antagonists that have been used most extensively for prostate cancer treatment 26 ; . Bicaluyamide and hydroxyflutamide HF, the active metabolite of flutamide ; are relatively pure AR antagonists in vivo, although HF has weak agonist activity at high concentrations in transient transfection assays 27-29 ; . While HF is an antagonist of the wildtype AR, it is an agonist for certain mutant ARs identified in prostate cancer patients and stimulates the growth of LNCaP prostate cancer cells, which express an AR with a threonine to alanine mutation in codon 877 T877A ; of the LBD 30; 31 ; . Significantly, this T877A mutation is found at increased frequency in prostate cancers that relapse after flutamide therapy, supporting the hypothesis that these prostate cancers in vivo behave similarly to LNCaP cells and are stimulated by the HF liganded T877A mutant AR 32. 1048685 Benazepril Related Compound G 15 mg ; 3- 1Ethoxycarbonyl-3-phenyl- 1S ; -propyl ; amino-2, 3, 4, 5tetrahydro-2-oxo-1H-1- ; -benzazepine ; -1-acetic acid, ethyl ester ; Bendroflumethiazide 200 mg ; Benoxinate Hydrochloride 200 mg ; Benzaldehyde 1 ml ; List Chemical ; Benzalkonium Chloride 5 ml of approx. 10% aqueous solution ; Benzethonium Chloride 500 mg ; Benzocaine 500 mg ; Benzoic Acid 300 mg ; Benzonatate 1 g ; 1, 4-Benzoquinone 200 mg ; Benzothiadiazine Related Compound A 100 mg ; 4-Amino-6chloro-1, 3-benzenedisulfonamide ; Benzphetamine Hydrochloride CIII 200 mg ; AS ; Benztropine Mesylate 200 mg ; Benzyl Alcohol 500 mg ampule ; Benzyl Benzoate 5 g ; 1-Benzyl-3-methyl-5-aminopyrazole Hydrochloride 25 mg ; Bephenium Hydroxynaphthoate 500 mg ; Berberine Chloride 50 mg ; Betahistine Hydrochloride 200 mg ; Betaine Hydrochloride 200 mg ; Betamethasone 200 mg ; Betamethasone Acetate 500 mg ; Betamethasone Benzoate 200 mg ; Betamethasone Dipropionate 125 mg ; Betamethasone Sodium Phosphate 500 mg ; Betamethasone Valerate 200 mg ; Betamethasone Valerate Related Compound A 50 mg ; Betamethasone 21-valerate ; AS ; Betaxolol Hydrochloride 200 mg ; Betazole Hydrochloride 200 mg ; Bethanechol Chloride 200 mg ; Bical8tamide 200 mg ; Bicalutamjde Related Compound A 25 mg ; N-[4-cyano-3 trifluoromethyl ; phenyl]-3-[ 4-fluoro-phenyl Bicalutamidw Related Compound B 10 mg ; RS ; -N-[4cyano-3- trifluoromethyl ; phenyl]-3- 3-fluorophenylsulfonyl ; 2-hydroxy-2-methylpropanamide ; Bile Salts 10 g and carbamazepine. Just anwser why i vomiting blood with stomach pain i vomiting blood why do have i have diarrhea and coughing aand vomiting. REISSMAN: A lot of pharmacy directors would agree with what Dr. Geierman just said. There's a lot of talk at the health plan level that if rebates were done away with, everybody's life would be a whole lot easier. The problem is that, for MCOs that are getting close to 9 percent back in rebate and keeping it all, it's a tough sell to the chief financial officer. How does one explain that costs next year will increase by 10 percent due to loss of rebates plus additional inflation increases? One of the interesting things I've seen is that a couple of pharmaceutical companies are now putting into their health plan contracts a mandate that a certain percentage, or all, of the rebate goes back to the medical groups if the medical groups are at risk for pharmacy, in order to get the discount. This may be a way to help level the playing field and ketorolac. Mifepristone and bicalutamide in their abilities to antagonize LNCaP cell growth in the presence of R1881 and charcoal-treated calf serum. Figure 9A shows the effects of different concentrations of R1881 on LNCaP growth after 10 d. These data recapitulate published findings of the response of LNCaP cells to different steroid hormones and antihormones 30 ; . Bicalutamide alone had a slightly inhibitory effect on LNCaP cell growth, especially at concentrations of at least 10 6 M Fig. 9B ; . However, bicalutamide did not antagonize 0.1 nM R1881 on LNCaP cell growth Fig. 9C ; . Mifepristone alone could stimulate LNCaP cell growth in a dose-dependent manner. However, when 10 5 M mifepristone was used, the cell number decreased, suggesting a toxic effect that this supraphysiologic concentration mifepristone may have toxic effects on the cells Fig. 9D ; . The effect of 0.1 nM R1881 on LNCaP cell growth was antagonized by mifepristone in a dose-dependent manner Fig. 9E. In bicalutamide monotherapy and combination therapy studies, anemia has occurred in 7%-8% of patients, compared with a 7% incidence seen with castration alone and pentoxifylline. MINNESOTA Minneapolis - University of Minnesota Charlotte Brown, Ph.D. RG ; Role of altered forms of laminin A C in the pathogenesis of Emery-Dreifuss EDMD ; muscular dystrophy $ 50, 303 7 - Year 3 Summary Researchers will identify patients with EDMD due to mutations in lamins A and C and investigate how the presence of the altered proteins in muscle cause disease. Laura Ranum, Ph.D. RG ; Murine model of myotonic dystrophy type 2 DM2 ; $ 110, 000 1 03 - Year 2 $ 110, 000 1 04 - Year 3 Summary Researchers propose to create a mouse model of DM2 to use as a tool to better understand pathogenic mechanisms of the disease process. Morayma Reyes, Ph.D. DG ; Use of multipotent adult progenitor cells MAPC ; as therapy for muscular dystrophy $ 45, 000 1 03 - Year 1 $ 45, 000 1 04 - Year 2 $ 45, 000 1 05 - Year 3 Summary Investigators propose to conduct studies of genetically reconstructed utrophin + ; mdx-MAPC and mdx-utrn MAPC transplants into mdx and mdx-utrn mice. For that, MAPC will be generated from mdx and mdx-utrn - mice. They will design retroviral and lentiviral constructs containing the truncated utrophin gene driven by a constitutive or a muscle specific promoter. Then, they will transduce the mdx-MAPC and mdx-utrn- MAPC with these vectors. Utrophin expression as well as its effects during ex vivo expansion and differentiation will be studied. Then, they will perform serial syngeneic transplants of genetically reconstructed MAPC into mdx mice and mdx-utrn mice. David Thomas, Ph.D. RG ; Engineering new molecular probes of muscle $ 79, 570 1 - Year 3 Summary Researchers are engineering new probes to understand the molecular movements that produce force in muscle, and to understand how these molecular movements change during the process of muscle degeneration. Wei Wang, M.D. DG ; AChR epitopes restricted by DR and DQ molecules relevant to myasthenia gravis mg ; $ 45, 000 7 1 03 - Year 1 $ 45, 000 7 1 04 - Year 2 $ 45, 000 7 1 05 - Year 3 Summary Investigators want to determine the epitope repertoire of anti-AChR CD4 + T helper cells recognized in association with the DR2, DR3, DR4, DQ6 or DQ8 molecules, to identify characteristics that correlate with susceptibility or resistance to mg. 10 03 ; prenatal testing notification letter environmental requisition form specimen outfit order form new ; infection control guidelines outbreak interventions selection & use of disinfectants picnet - provincial infection control network norwalk-like virus fact sheet guide to the laboratory investigation of gi disease outbreaks gi outbreak decontamination managing outbreaks of gastroenteritis guidelines for the control of antibiotic resistant organisms ili outbreak laboratory form handwashing poster infection control guidelines for the physician's office environmental health framework monitoring dw systems final ; nov 04 safe dw public health laboratory surveillance water sampling protocol bioterrorism response advisory team brat ; exposure to biological agents response plan hepatitis services march 2000 - informed decision-making about mother-to-child transmission of hepatitis c virus by breastfeeding , mark bigham md, frcpc, mel krajden, md, frcpc and trihexyphenidyl. Kevin's case manager asked him what he wanted to do next. Kevin decided to begin working on a plan that included reducing his drinking to every other day, attending a money management group once, and thinking about opening a bank account to work on saving money for housing. After four months, Kevin was taking medication. After two more months, he decided to apply for and got into a residential treatment setting where he was able to stop substance use, take some classes, and become involved in Alcoholics Anonymous. He stayed there for two years and then transitioned into his own apartment. He had reconnected with one of his children, and was proud to be involved with her family. Casodex bicalutamide Compounds and Cell Lines Exemestane and 17-hydroexemestane were provided by Pfizer. Fulvestrant ICI 182, 780, Faslodex ; and bicalutamide Casodex ; were provided by Dr. Alan E. Wakeling and Dr. Barrington J.A. Furr AstraZeneca Pharmaceuticals, Macclesfield, United Kingdom ; , respectively. All other and celecoxib and Buy bicalutamide. Reducing serum testosterone below castrate levels in patients with metastatic prostate cancer [42, 43]. Objective and subjective responses, and survival and duration of response were comparable [42, 43]. However, leuprorelin was better tolerated [42, 43] leading to fewer treatment withdrawals than with DES [43]. Fewer adverse cardiovascular events occurred with leuprorelin than with DES [42]. In a crossover study, patients reported that their general health and social life were better with leuprorelin than with DES [44]. seen largely in M0 patients. The authors conclude that the data "provide consistent support for the benefits of immediate treatment". A further study by the Eastern Cooperative Oncology Group ECOG ; was conducted in 98 patients who had undergone radical prostatectomy and had pelvic lymph node metastases D1 ; [47]. Compared with deferred therapy, immediate antiandrogen therapy improved survival and reduced the risk of recurrence [47]. Other data also support immediate treatment versus deferred treatment in advanced disease [45, 46], including Study 30846 of the European Organisation for Research and Treatment of Cancer EORTC ; [46]. This prospective randomised study included 412 patients with positive lymph nodes who did not undergo a previously planned radical prostatectomy, but were instead randomised to immediate or deferred hormone therapy. Early data from 84 patients indicate that time to distant metastases was prolonged by immediate therapy. data from trials in 8275 men with metastatic or locally advanced prostate cancer indicated that survival was increased by 23 % by the addition of an antiandrogen to an LHRH analogue or orchiectomy [48]. However, the range of uncertainty regarding the true size of the benefit ranged from 0 % to about 5 %. Nevertheless, some studies using leuprorelin as a daily injection alongside antiandrogens indicate beneficial effects of MAB on progression and survival [4953] The largest of these was a double-blind randomised comparative study in 603 men with metastatic prostate cancer [51 53]. Patients who received leuprorelin and flutamide had longer progression-free survival than those who received leuprorelin alone 16.5 vs 13.9 months; p 0.039 ; . The median length of survival was also greater in patients who received MAB 35.6 vs 28.3 months; p 0.035 ; . The differences between the treatments were particularly evident for men with minimal metastatic disease vertebrae only ; and good performance status [5153]. However, a randomised multicentre study [54] in 241 men, in which leuprorelin was compared with leuprorelin plus flutamide in advanced prostate cancer found no significant differences in time to progression or survival. The authors concluded that the benefits of MAB in this study were "at best marginal". A further 160-week randomised, multicentre, open-label trial in 813 patients assessed the efficacy and tolerability of two antiandrogens, bicalutamide and flutamide, each combined with one-month depot preparations of leuprorelin or goserelin, in patients with stage D2 prostate cancer. The percentages of patients whose tumours progressed or who died during the study were similar for goserelin plus antiandrogen and leuprorelin plus antiandrogen therapies [55]. There was no long-term. Initial decrease in shortening which, however, was frequently followed by spontaneous activity. Nevertheless, dependence of the observed pharmacological effects upon initial shortening is unlikely since we observed that initial muscle shortening and pharmacological effects do not correlate with each other as can be derived from Figs 2B-8B. Further pilot experiments, performed on two papillary muscles, have shown that the negative inotropic effect of adrenaline is not specific to isotonic contraction, but is also evident in the isometrically beating papillary muscle. Furthermore, the negative inotropic effect of adrenaline is not restricted to a stimulation rate of 0 5 Hz, since additional pilot experiments at 0'2, 1 and 2 Hz yielded qualitatively similar effects. Ligand-binding studies have proved the existence of cz-adrenoceptors in the myocardium Steinberg & Bilezikian, 1982 ; . The density of myocardial ac-adrenoceptors varies with species and the myocardium of the rat in particular possesses a high number of az-adrenoceptor binding sites Mukherjee et al. 1983; Endoh, Hiramoto, Ishihata, Takanashi & Inui, 1991 ; . According to most studies the stimulation of myocardial az-adrenoceptors results in a positive inotropic effect for review see Fedida, 1993; Terzic et al. 1993 ; . In rat myocardium, soon after exposure to phenylephrine and prior to the positive inotropic effect, a small and transient negative inotropy has been observed and sumatriptan. Poietins stimulate the progenitor cells until they transform into the appropriate young blood cell known as a blast cell. As a result, I contend that Immtech' science is real, efficacious and it is being recognized. s The consortium funds scientific leaders in the fields of drug metabolism and transport, combinatorial chemistry, molecular biology, rational drug design, anti-fungal and tuberculosis research, among other disciplines. Dr. Tidwell opines that it is likely both the diamidine compounds and the research and business paradigm that attracts such " world class"talent to Immtech' consortium structure. s The consortium scientists also have a stake in Immtech through share ownership. Lead scientists have received stock option packages. The universities in the consortium received. In fact, dea head thomas constantine recently stated in a washington times interview that many times people talk about the nonviolent drug offender. Exactly how antidepressants influence pain and sleep is still unknown. The number of calories that you need to eat each day to - published: 07 30 2008 how many calories to lose weight and buy acetaminophen. 3 If a student nurse realizes that he or she has committed a drug error, it is important--in the student's educational process--to emphasize which of the following? a. The student bears no legal responsibility when giving medications. b. The major legal responsibility is on the health care institution where the student is placed for clinical and therefore the school and faculty are not legally liable. c. Student nurses lack the needed knowledge for medications and therefore should never give drugs to their patients. d. Once the student has committed a medication error, his or her responsibility is to the patient and to being honest and accountable. Responsibility continues from there with constant monitoring of the patient and his or her physiologic and emotional responses to the error. 4 The JCAHO guidelines now include which of the following statements? a. Disruptive physician behavior is not addressed at all within the guidelines and or scope of medical errors with the JCAHO. A number of new treatment approaches are being developed to target the growth of cancer cells outside the surgical margins or radiation field, thereby improving the outcome for patients diagnosed with locally advanced disease. As prostate cancer is a hormone-dependent tumour, primarily responding to testosterone, one potential treatment option is to block the effect of androgens by hormonal therapy. `Casodex' bicalutamide ; , a non-steroidal antiandrogen, was developed as part of AstraZeneca's continuing quest for innovative treatments for prostate cancer. `Casodex' 150 mg can be used as either adjuvant to standard treatments of curative intent or as monotherapy in patients with locally advanced prostate cancer. This offers a therapeutic alternative to medical or surgical castration in patients for whom immediate hormone therapy is indicated. Bicalutamide inhibited the androgen-dependent induction of PSA expression Fig. 5A ; . However, in C4-2 cells, constitutive PSA expression was unaffected, or slightly increased in the presence of 10M bicalutamide Fig. 5A ; . Similarly, in LNCaP cells, bicalutamide inhibited the androgeninduced activity of hARGal4 Fig. 5B ; . Conversely, in C4-2 cells, bicalutamide had no effect on, or slightly increased, androgen-independent hARGal4 activity Fig. 5B ; . These data suggest that bicalutamide is unable to inhibit AF-2 independent AR activity. To further test this hypothesis, we assessed whether the AR AF-2 mutants V716R and E897K could be further repressed by bicalutamide in LNCaP cells. As observed previously, these hARGal4 mutants with abrogated AF-2 function were able to weakly support androgen-dependent transcription Fig. 5C ; . However, this residual androgen-induced hARGal4 activity was not blocked by 10M bicalutamide Fig. 5C ; . To verify that the lack of effect of bicalutamide on ligand-independent AR activity was specifically due to AF-2 independent activity, and not a general resistance of C4-2 cells to antiandrogens, we tested whether bicalutamide could inhibit ligand-induced, AF-2-dependent AR activity in ADI C4-2 cells. As demonstrated in Fig. 5D, bicalutamide was able to effectively inhibit androgen-induced PSA mRNA expression in C4-2 cells. Similarly, when the AR-Gal4 system was employed, bicalutamide effectively inhibited the component of hARGal4 activity that resulted from androgen induction, but was unable to affect the constitutive, AF-2-independent component of hARGal4 activity in C4-2 cells Fig. 5E ; . C4-2 cells are able to proliferate in vitro in an AR-dependent manner in the absence of exogenous androgens 12, 32 ; . Because our results demonstrate that bicalutamide selectively affects AF-2-dependent ligand-dependent vs. AF-2 independent ligand-independent AR activity in C4-2 cells, we used bicalutamide to test whether ADI C4-2 growth was indeed AF-2 independent and ligand-independent. Under conditions which mimic a complete androgen blockade, we observed no effect on the growth of C4-2 cells compared with androgen-depletion alone Fig. 5F ; . These data suggest that C4-2 cells are ADI due to constitutive, ligand-independent, AF-2independent AR activity. Carcinoma of the prostate is the most commonly diagnosed cancer in men. The current pharmacological treatment of choice for progressive androgen-dependent prostate cancer is the nonsteroidal antiandrogen, bicalutamide, either as monotherapy or with adjuvant castration or luteinizing hormone-releasing hormone superagonists to block the synthesis of endogenous testosterone. To date, no nonsteroidal or antagonist-bound androgen receptor AR ; structure is available. We solved the x-ray crystal structure of the mutant W741L AR ligand-binding domain bound to R-bicalutamide at 1.8- resolution. This mutation confers agonist activity to bicalutamide and is likely involved in bicalutamide withdrawal syndrome. The three-dimensional structure demonstrates that the B ring of R-bicalutamide in the W741L mutant is accommodated at the location of the indole ring of Trp-741 in the WT AR bound to dihydrotestosterone. Knowledge of the binding mechanism for R-bicalutamide will provide molecular rationale for the development of new antiandrogens and selective AR modulators. JPET #81109 The CYP2D6 phenotype was determined by using dextromethorphan 3 methoxy17-methylmorphinan monohydrate ; as the probe drug as previously described Labb et al., 2000 ; . Individuals with a dextromethorphan: dextrorphan metabolic ratio of 0.3 were considered poor metabolizers. A 10 ml blood sample was obtained for genotyping. DNA was extracted from peripheral blood lymphocytes and CYP2D6 * 1A, CYP2D6 * 3, CYP2D6 * 4, CYP2D6 * 5, CYP2D6 * 6, CYP2D6 * 7 and CYP2D6 * 8 alleles were determined using a classic multiplex-PCR Stuven et al., 1996. What is Bicalutamide Fig 2. Incidence and severity of breast pain in the bicalutamide B ; , bicalutamide-tamoxifen BT ; , and bicalutamide-anastrozole BA ; groups. All pain degrees, P .006; B versus BT, P .001; mild pain, P .02. NDA 21-316 Page 11 ALTOCOR has been shown to reduce Total-C, LDL-C, and TG and increase HDL-C in patients with hypercholesterolemia. Near maximal response was observed after four weeks of treatment and the response was maintained with continuation of therapy for up to 6 months. In a 12-week, multicenter, placebo-controlled, double-blind, dose-response study in adult men and women 21 to 70 years of age with primary hypercholesterolemia, once daily administration of ALTOCOR 10 to 60 mg in the evening was compared to placebo. ALTOCOR produced dose related reductions in LDL-C and Total-C. ALTOCOR produced mean reductions in TG across all doses that varied from approximately 10% to 25%. ALTOCOR produced mean increases in HDL-C across all doses that varied from approximately 9% to 13%. The lipid changes with ALTOCOR treatment in this study, from baseline to endpoint, are displayed in Table III. Table III ALTOCORTM vs. Placebo Mean Percent Change from Baseline After 12 Weeks. Wirth M, Tyrrell C, Sanchez-Chapado M et al. Prostate Cancer and Prostatic Diseases 2007; 10: 87 The ongoing bicalutamide CASODEX ; Early Prostate Cancer Programme EPC ; is evaluating the addition of bicalutamide 150mg daily to standard care i.e. radiotherapy RT ; , radical prostatectomy RP ; or watchful waiting WW ; . The hypothesis being to identify whether bicalutamide can reduce the risk of disease progression as well as improve survival in localised T1-2, N0 or Nx, M0 ; or locally advanced prostate cancer T3-4, any N, M0 or any T, N + , M0 ; the largest prostate cancer study n 8113 ; to date and consists of 3 trials Trials 23, 24 and 25 ; . The overall EPC programme with 7.4 years' follow-up, has identified that bicalutamide 150mg significantly improves overall survival p 0.003 ; when used as adjuvant to radiotherapy. In addition significantly reduces the risk of disease progression in patients with locally advanced disease. However in localised disease there is no significant difference in disease progression or overall survival and it has been concluded that bicalutamide 150mg should not be used as immediate therapy for patients with localised prostate cancer. This paper describes the results of Trial 24 n 3603 ; , conducted in Europe, Mexico, South Africa, Israel and Australia. Patients who were treated with RP 45% ; , RT 18% ; or WW 35% ; were randomised 1: to bicalutamide 150mg daily or placebo until disease progression. Primary end-points were objective disease progression PFS ; and tolerability. At 7 years' median follow-up, the addition of bicalutamide 150mg significantly improved PFS in patients with locally advanced disease, reducing the risk of disease progression by 34% p 0.001 ; and the risk of PSA progression by 55% p 0.001 ; . However, there was no significant difference in overall survival 27.7% vs 30.8. Radiotherapy has significantly improved survival in men with locally advanced prostate cancer compared to radiotherapy alone, the drug bicalutamide may offer a. 71 ; PFIZ ER LIMITED [GB GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ GB ; . only for seulement pour GB ; 71 ; PFIZ ER INC. [US US]; 235 East 42nd Street, New York, NY 10017 US ; . for all designated States except pour tous les tats dsigns sauf GB US ; 72, 75 ; MATHIAS, John, Paul [GB GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ GB ; . 74 ; OOD, David, J. et al. etc.; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ GB ; . 81 ; mg MK MN MW MX ZW. 84 ; AP BW ml MR NE SN TD C07D 213 82, 401 A61K 31 455, A61P 37 00 11 ; 2005 009965 21 ; PCT IB2004 002368 22 ; 13 Jul juil 2004 13.07.2004 ; 25 ; en 30 ; 0317484.4 26 ; en 25 Jul juil 2003 25.07.2003 ; GB 13 ; A1. Hematocrit HCT ; and the platelet count PLT ; CDK-1 CYCLIN-DEPENDENT KINASE INHIBITOR ; : a regulator of cell growth; an enzyme inhibitor CDUS COLOR-FLOW DOPPLER ULTRASOUND ; : an ultrasound method that more clearly images tumors by observing the Doppler shift in sound waves caused by the rapid flow of blood through tiny blood vessels that are characteristic of tumors CEA CARINOEMBRYONIC ANTIGEN ; : a fetal antigen or protein that may be expressed by PC that is aggressive and often androgenindependent CELL-MEDIATED IMMUNITY: immunity dependent upon T-cells' recognition of an antigen and their subsequent destruction of cells bearing the antigen CGA: chromogranin A; a small cell prostate cancer or neuroendocrine cell marker; a progressive increase in CGA indicates an aggressive clone of PC cells that often metastasizes to nodes, liver and lungs CHB COMBINATION HORMONE BLOCKADE ; : also referred to as CHT, MAB, TAB or ADT androgen deprivation therapy therapy usually involving an LHRH agonist and an anti-androgen; may involve other agents such as Proscar or prolactin inhibitors such as Dostinex; preferred term is ADT with number attached to show number of agents e.g. ADT3 Flutamide, Lupron, Proscar ; or ADT3 FLP ; CHEMOPREVENTION: the use of a pharmaceutical or other substance to prevent the development of cancer CHEMOTHERAPY: the use of pharmaceuticals or other chemicals to kill cancer cells; in many cases chemotherapeutic agents kill not only cancer cells but also other cells in the body, which makes such agents potentially very dangerous CHROMOSOME: a threadlike linear strand of DNA and associated proteins in the nucleus of cells that carries the genes and functions in the transmission of hereditary information CHT COMBINED HORMONAL THERAPY ; : the use of more than one hormone in therapy; especially the use of LHRH analogs e.g., Lupron, Zoladex ; to block the production of testosterone by the testes, plus anti-androgens e.g., Casodex bicalutamide ; , Eulexin flutamide ; , Anandron Nilutamide ; , or Androcur Cyproterone ; to compete with DHT and with T testosterone ; for cell sites thereby depriving cancer cells of DHT and T needed for growth; also referred to as CHB, MAB, TAB; the preferred term is ADT CLINICAL TRIAL: a carefully planned experiment to evaluate a treatment or a medication often a new pharmaceutical ; for an unproven use; Phase I trials are very preliminary short-term trials involving a few patients to see if drugs have any activity or any serious side effects; Phase II trials may involve 20 to 50 patients and are designed to estimate the most active dose of a new drug and determine its side effects; Phase III trials involve many patients and compare a new therapy against the current standard or best available therapy COLLIMATOR: a device used to define the size and shape of a radiation beam in radiation therapy treatment machines; A collimator typically consists of large blocks of heavy metals, such as steel or tungsten, moved by mechanical motors to define rectangular fields; see IMRT COMBINATION THERAPY: see CHT or CHB; ADT with designation ADT1 vs ADT2 or ADT3 is preferred since this communicates the number of drugs used in the androgen deprivation therapy; ADT also more clearly communicates the mechanism of this form of treatment COMPLETE RESPONSE CR ; : total disappearance of all evidence of disease using physical examination, laboratory studies and radiologic imaging; a criterion for evaluating the efficacy of a particular anticancer therapy; also see partial response COMPLICATION: an unexpected or unwanted effect of a treatment, pharmaceutical or other procedure CONCORDANCE: the agreement in findings that support the accuracy of a particular investigation or treatment; concordance is a critical concept in studies to diagnose, stage and treat PC CONFORMAL THERAPY: the use of careful planning and delivery techniques designed to focus radiation on the areas of the prostate and surrounding tissue which need treatment and protect areas which do not need treatment; three-dimensional conformal radiation therapy 3DCRT ; is a sophisticated form of this method CONTRACTURE: scarring which can occur at the bladder neck after a radical prostatectomy or radiation therapy and that results in narrowing of the passage between the bladder and the urethra; same as stricture COQ10 COENZYME Q10 ; : important in cardiac function; a substance that energizes the mitochondria within the heart cells and allows them to function better; an anti-oxidant that protects LDL cholesterol from oxidation CORPORA CAVERNOSA: a part of a man's penis that fills with blood when he is sexually excited, giving the organ the stiffness required for intercourse CORPORA SPONGIOSUM: a spongy chamber in a man's penis that fills with blood when he is sexually excited, giving the organ the stiffness required for intercourse COWPER'S GLANDS: a pair of pea-sized glands that lie beneath the prostate gland, named after the English surgeon William Cowper 1660-1709 ; . Cowper's glands secrete an alkaline fluid that forms part of the semen. This fluid neutralizes the acidic environment of the urethra, thereby protecting the sperm CRYOABLATION: see cryosurgery CRYOSURGERY: the use of liquid nitrogen probes to freeze a particular organ to extremely low temperatures to kill the tissue, including any cancerous tissue; when used to treat prostate cancer, the cryoprobes are guided by transrectal ultrasound CRYOTHERAPY: see cryosurgery CT SCAN: computerized or computed tomography; see cat scan CYPROTERONE: an anti-androgen with progestational activity CYSTITIS: inflammation of the bladder that may be caused by infection or chemical injury or radiation; characterized by increased urinary frequency, discomfort on urination and often red blood cells, white blood cells and or bacteria in the urine CYSTOSCOPE: an instrument used by physicians to look inside the bladder and the urethra CYSTOSCOPY: the use of a cystoscope to look inside the bladder and the urethra CYTOCHROME P-450 DEPENDENT 14-DEMETHYLATION: an enzyme system that is important in the endocrine pathways of hormone. RTOG#P-0126: Phase III randomized study of high dose 3D-CRT versus standard dose 3D-CRT in patients treated for localized prostate cancer. Available at Jefferson and Frankford. RTOG#0232: Phase III study comparing combined external beam radiation and transperineal interstitial permanent breachytherapy with brachytherapy alone for selected patients with intermediate risk prostatic cancer. Available at Jefferson, Frankford and Methodist. RTOG#0233: Phase II randomized trial for patients with muscle-invading bladder cancer evaluating transurethral surgery and BID irradiation plus either paclitaxel and cisplatin or 5-fluorouracil and cisplatin followed by selective bladder preservation and gemcitabine paclitaxle cisplatin adjuvant chemotherapy. Available at Jefferson, Chestnut Hill, Riddle, Methodist, Frankford. IRB #02C.493: Use of Androgen Suppression for glandular downsizing: A Phase II trial using bicalutamide Casodex ; 150mg IND#65, 504 ; prior to definitive management of localized adenocarcinoma of the prostate. Available at Jefferson. IRB #02C.172: Phase I pilot study of Samarium 153 combined with neoadjuvant hormonal therapy and radiation therapy in men with locally advanced prostate cancer. Available at Jefferson. Bicalutamide tablets Bicalutam9de, bicalktamide, bicalutamids, bucalutamide, bicalu5amide, bicalutamidr, bicaluhamide, bicalutamde, gicalutamide, bifalutamide, bicalutamid3, bicaluatmide, bicakutamide, biclautamide, bicaalutamide, bicalutamise, bocalutamide, bicaluamide, bicslutamide, biicalutamide, b9calutamide, bicalugamide, bicalufamide, bcalutamide, bicalutamife, ibcalutamide, bicalutqmide, bbicalutamide, bicxlutamide, bicalu6amide, bicalutam8de, biclutamide, bicaltuamide, bicaputamide, bicalutamied, bicalutamkde, bicqlutamide, bicalutwmide, bicalutamixe, b8calutamide, bcialutamide, bicalutaide, biczlutamide, bicalutamidde, bicalutamidee, bicaluyamide, bidalutamide, vicalutamide, bicalutamid, bicalutamiee. Bicalutamide oral, casodex bicalutamide, what is bicalutamide, bicalutamide tablets and bicalutamide alcohol. Bicalutamide 50, bicalutamide 50 mg, bicalutamide product information and bicalutamide tablets or bicalutamide salvage radiotherapy. Bicalutamide alcohol Avandia 12 mg, vytorin 80 20, reticulocytosis in thalassemia, detrol for incontinence and naris green. Soy isoflavone wiki, magnetic resonance imaging of the heart, medical lab result evaluation and valium next day or toco johns. © 2006-2009 World.free0host.com -All Rights Reserved.